New Page 1
 

COPD-X Menu
COPD-X Menu COPD-X Home Page COPD-X Guidelines Management Tools Case Statements News & Resources COPD Institute Contact Us
COPD-X Menu

 

References 1 - 50

Refs 1 - 50 Refs 51 - 100 Refs 101 - 150 Refs 151 - 200 Refs 201 - 250 Refs 251 - 291
Note: [return to text] - goes to the last page in viewed in COPD-X regardless of reference number.
 
1 Australian Institute of Health and Welfare, Chronic diseases and associated risk factors in Australia, 2006. 2006, AIHW: Canberra.
2 The Thoracic Society of Australia and New Zealand New Zealand Branch and Asthma and Respiratory Foundation of New Zealand, The burden of COPD in New Zealand. 2003.
3 The Australian Lung Foundation, Case Statement. Chronic Obstructive Pulmonary Disease (COPD). 2001, The Australian Lung Foundation: Brisbane.
4 Crockett, A., J. Cranston, and J. Moss, Chronic obstructive pulmonary disease (COPD). Economic Case Statement. 2002. p. 5.
5 Wagner, E.H., B.T. Austin, and M. Von Korff, Organizing care for patients with chronic illness. Milbank Q, 1996. 74(4): p. 511-44.
6 National Health and Medical Research Council, A guide to the Development, Implementation and Evaluation of Clinical Practice Guidelines. 1998, NHMRC: Canberra.
7 NHLBI/WHO Workshop Report, Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD): Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. April 2001, National Institutes of Health - National Heart, Lung and Blood Institute: Bethesda, MD.
8 Fletcher, C. and R. Peto, The natural history of chronic airflow obstruction. Br Med J, 1977. 1(6077): p. 1645-8.
9 Burrows, B., et al., Quantitative relationships between cigarette smoking and ventilatory function. American Rev Respir Dis, 1977. 115(2): p. 195-205.
10 Global Initative for Chronic Obstructive Lung Disease, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2007). p. 2.
11 Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global Strategy for the Diagnosis, Management and Prevention of COPD. 2006.
12 Matheson, M.C., et al., Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease. Thorax, 2005. 60(8): p. 645-51.
13 Gan, W.Q., et al., Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Res, 2006. 7: p. 52.
14 Peto, R., et al., The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis, 1983. 128(3): p. 491-500.
15 Casanova, C., et al., Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2005. 171(6): p. 591-7.
16 Celli, B.R., et al., The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med, 2004. 350(10): p. 1005-12.
17 Connors, A.F., Jr., et al., Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) [published erratum appears in Am J Respir Crit Care Med 1997;155:386]. Am J Respir Crit Care Med, 1996. 154(4 Pt 1): p. 959-67.
18 National Emphysema Treatment Trial Research, G., Patients at High Risk of Death after Lung-Volume-Reduction Surgery. N Engl J Med, 2001. 345(15): p. 1075-1083.
19 Tashkin, D.P., et al., Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med, 1996. 153(6 Pt 1): p. 1802-11.
20 Anthonisen, N.R., J.E. Connett, and R.P. Murray, Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med, 2002. 166(5): p. 675-9.
21 Medical Research Council Working Party, Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet, 1981. 1(8222): p. 681-6.
22 Nocturnal Oxygen Therapy Trial Group, Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med, 1980. 93(3): p. 391-8.
23 Georgopoulos, D. and N.R. Anthonisen, Symptoms and signs of COPD, in Chronic Obstructive Pulmonary Disease, N.S. Cherniack, Editor. 1990, WB Saunders: Toronto. p. 357-363.
24 Thompson, A.B., et al., Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis, 1992. 146(2): p. 389-95.
25 Bestall, J.C., et al., Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax, 1999. 54(7): p. 581-6.  [return to text]
26 Badgett, R.G., et al., Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? Am J Med, 1993. 94(2): p. 188-96.
27 Kelly, C.A. and G.J. Gibson, Relation between FEV1 and peak expiratory flow in patients with chronic airflow obstruction. Thorax, 1988. 43(4): p. 335-6.
28 NHLBI/WHO Workshop Report, Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD): Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. April 2001, National Institutes of Health - National Heart, Lung and Blood Institute: Bethesda, MD. p. 6.
29 Wilt, T.J., et al., Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Evid Rep Technol Assess (Summ), 2005(121): p. 1-7.
30 Miller, M.R., et al., Standardisation of spirometry. Eur Respir J, 2005. 26(2): p. 319-38.
31 Sourk, R.L. and K.M. Nugent, Bronchodilator testing: confidence intervals derived from placebo inhalations. Am Rev Respir Dis, 1983. 128(1): p. 153-7.
32 Pellegrino, R., et al., Interpretative strategies for lung function tests. Eur Respir J, 2005. 26(5): p. 948-68.
33 British Thoracic Society, BTS statement on criteria for specialist referral, admission, discharge and follow-up for adults with respiratory disease. Thorax, 2008. 63 Suppl 1: p. i1-i16.
34 Blanco, I., et al., Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J, 2006. 27(1): p. 77-84.
35 American Thoracic Society/European Respiratory Society, American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med, 2003. 168(7): p. 818-900.
36 McCord, J. and S. Borzak, Multifocal atrial tachycardia. Chest, 1998. 113(1): p. 203-9.
37 National Heart Lung and Blood Institute, Morbidity and Mortality: Chartbook on Cardiovascular, Lung, and Blood Diseases [2004 edition available http://www.nhlbi.nih.gov/resources/docs/cht-book.htm. 1998, US Department of Health and Institutes of Health: Bethesda, MD.
38 Decramer, M., et al., Systemic effects of COPD. Respir Med, 2005. 99 Suppl B: p. S3-10.
39 Holguin, F., et al., Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest, 2005. 128(4): p. 2005-11.
40 Borrill, Z., et al., Retrospective analysis of evidence base for tests used in diagnosis and monitoring of disease in respiratory medicine. BMJ, 2003. 327(7424): p. 1136-8.
41 Vathenen, A.S., et al., High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis, 1988. 138(4): p. 850-5.
42 Gross, N.J., et al., Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis, 1989. 139(5): p. 1188-91.
43 Higgins, B.G., et al., Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J, 1991. 4(4): p. 415-20.
44 Belman, M.J., W.C. Botnick, and J.W. Shin, Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1996. 153(3): p. 967-75.
45 Jenkins, S.C., et al., Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest, 1987. 91(6): p. 804-7.
46 Guyatt, G.H., et al., Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis, 1987. 135(5): p. 1069-74.
47 Berger, R. and D. Smith, Effect of inhaled metaproterenol on exercise performance in patients with stable "fixed" airway obstruction. Am Rev Respir Dis, 1988. 138(3): p. 624-9.
48 Hay, J.G., et al., Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J, 1992. 5(6): p. 659-64.
49 Ram, F.S. and P. Sestini, Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax, 2003. 58(7): p. 580-4.
50 Appleton, S., et al., Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2006. 3: p. CD006101. [return to text]

 

Next Page Previous Page